Envestnet Asset Management Inc Bio Line Rx Ltd. Transaction History

Envestnet Asset Management Inc

  • $281 Billion
  • Q2 2024

A detailed history of Envestnet Asset Management Inc transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 213,833 shares of BLRX stock, worth $134,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares
213,833
Previous 54,405 293.04%
Holding current value
$134,714
Previous $60,000 101.67%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024
BUY
$0.56 - $0.86 $89,279 - $137,108
159,428 Added 293.04%
213,833 $121,000
Q1 2024

May 13, 2024
BUY
$1.03 - $1.56 $7,990 - $12,102
7,758 Added 16.63%
54,405 $60,000
Q4 2023

Feb 13, 2024
SELL
$1.31 - $1.86 $15,049 - $21,367
-11,488 Reduced 19.76%
46,647 $73,000
Q3 2023

Nov 13, 2023
SELL
$1.23 - $2.45 $12,656 - $25,210
-10,290 Reduced 15.04%
58,135 $105,000
Q2 2023

Aug 04, 2023
SELL
$0.96 - $1.78 $29,271 - $54,273
-30,491 Reduced 30.83%
68,425 $109,000
Q1 2023

May 11, 2023
BUY
$0.56 - $0.89 $55,392 - $88,035
98,916 New
98,916 $88,000
Q3 2022

Nov 10, 2022
SELL
$0.88 - $1.91 $18,929 - $41,086
-21,511 Reduced 41.89%
29,839 $28,000
Q2 2022

Aug 03, 2022
SELL
$1.06 - $1.82 $18,868 - $32,396
-17,800 Reduced 25.74%
51,350 $66,000
Q1 2022

May 04, 2022
SELL
$1.46 - $2.18 $77,488 - $115,701
-53,074 Reduced 43.42%
69,150 $118,000
Q4 2021

Feb 04, 2022
BUY
$1.98 - $3.06 $157,006 - $242,645
79,296 Added 184.72%
122,224 $249,000
Q3 2021

Oct 07, 2021
BUY
$2.65 - $3.35 $113,759 - $143,808
42,928 New
42,928 $118,000

Others Institutions Holding BLRX

# of Institutions
37
Shares Held
4.29M
Call Options Held
49.9K
Put Options Held
122K
View Full List

About BioLineRx Ltd.

BLRX Quotes by TradingView
  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $38.8M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email